Thomas Meyer
Concepts (481)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Water | 29 | 2020 | 464 | 7.550 |
Why?
| | Ruthenium | 22 | 2020 | 34 | 5.490 |
Why?
| | Organometallic Compounds | 21 | 2014 | 111 | 4.620 |
Why?
| | Catalysis | 29 | 2020 | 319 | 2.850 |
Why?
| | Oxidation-Reduction | 41 | 2020 | 1059 | 2.700 |
Why?
| | Protons | 12 | 2016 | 91 | 2.570 |
Why?
| | Electron Transport | 16 | 2016 | 115 | 2.140 |
Why?
| | Titanium | 10 | 2013 | 82 | 2.100 |
Why?
| | Electrodes | 13 | 2020 | 114 | 1.800 |
Why?
| | Oxygen | 8 | 2020 | 943 | 1.550 |
Why?
| | Electrochemistry | 14 | 2017 | 80 | 1.490 |
Why?
| | Electron Transport Complex IV | 4 | 2016 | 59 | 1.390 |
Why?
| | Electrochemical Techniques | 7 | 2020 | 51 | 1.380 |
Why?
| | Alu Elements | 5 | 2025 | 28 | 1.310 |
Why?
| | Coordination Complexes | 6 | 2020 | 13 | 1.280 |
Why?
| | Electrons | 9 | 2013 | 86 | 1.240 |
Why?
| | Tin Compounds | 5 | 2020 | 17 | 1.210 |
Why?
| | Molecular Structure | 18 | 2014 | 508 | 1.190 |
Why?
| | Photochemical Processes | 6 | 2013 | 108 | 1.070 |
Why?
| | 2,2'-Dipyridyl | 3 | 2013 | 6 | 1.070 |
Why?
| | Models, Chemical | 6 | 2013 | 268 | 1.060 |
Why?
| | Hylobates | 3 | 2016 | 8 | 1.040 |
Why?
| | Solar Energy | 4 | 2013 | 34 | 1.030 |
Why?
| | Amyotrophic Lateral Sclerosis | 6 | 2024 | 87 | 0.890 |
Why?
| | Chlorides | 2 | 2015 | 140 | 0.860 |
Why?
| | Surface Properties | 10 | 2017 | 414 | 0.840 |
Why?
| | Copper | 2 | 2015 | 109 | 0.820 |
Why?
| | Benzoquinones | 2 | 2014 | 48 | 0.820 |
Why?
| | Pyridines | 5 | 2013 | 508 | 0.820 |
Why?
| | Amides | 2 | 2014 | 93 | 0.790 |
Why?
| | Nanostructures | 3 | 2013 | 108 | 0.790 |
Why?
| | Long Interspersed Nucleotide Elements | 3 | 2022 | 30 | 0.780 |
Why?
| | Oligopeptides | 3 | 2013 | 273 | 0.780 |
Why?
| | Coloring Agents | 3 | 2020 | 86 | 0.780 |
Why?
| | Polymers | 2 | 2017 | 495 | 0.700 |
Why?
| | Peptides | 5 | 2014 | 986 | 0.700 |
Why?
| | Ammonia | 2 | 2019 | 62 | 0.650 |
Why?
| | Osmium | 2 | 2013 | 4 | 0.640 |
Why?
| | Metal Nanoparticles | 4 | 2015 | 88 | 0.640 |
Why?
| | Papillomavirus Infections | 4 | 2025 | 331 | 0.630 |
Why?
| | Nitrogen Cycle | 1 | 2019 | 11 | 0.620 |
Why?
| | Kinetics | 11 | 2014 | 1679 | 0.610 |
Why?
| | Paracoccus denitrificans | 2 | 2015 | 3 | 0.590 |
Why?
| | Genome | 8 | 2018 | 292 | 0.580 |
Why?
| | Retroelements | 7 | 2025 | 47 | 0.580 |
Why?
| | Enzymes, Immobilized | 2 | 2015 | 30 | 0.570 |
Why?
| | Photochemistry | 5 | 2012 | 135 | 0.550 |
Why?
| | Gold | 3 | 2015 | 125 | 0.540 |
Why?
| | Photosynthesis | 4 | 2014 | 103 | 0.540 |
Why?
| | Light | 3 | 2020 | 383 | 0.530 |
Why?
| | Phylogeny | 4 | 2014 | 898 | 0.530 |
Why?
| | Minisatellite Repeats | 1 | 2016 | 42 | 0.520 |
Why?
| | Hydroquinones | 2 | 2012 | 29 | 0.490 |
Why?
| | Thermus thermophilus | 2 | 2014 | 7 | 0.480 |
Why?
| | Hydrogen-Ion Concentration | 6 | 2015 | 566 | 0.460 |
Why?
| | Silver | 1 | 2015 | 39 | 0.460 |
Why?
| | Chlorine | 1 | 2015 | 61 | 0.460 |
Why?
| | Cytochrome b Group | 1 | 2014 | 18 | 0.450 |
Why?
| | Oxides | 2 | 2013 | 45 | 0.450 |
Why?
| | Proline | 3 | 2013 | 80 | 0.440 |
Why?
| | Ferric Compounds | 1 | 2014 | 55 | 0.420 |
Why?
| | NAD | 1 | 2014 | 77 | 0.420 |
Why?
| | Fluorine | 1 | 2013 | 16 | 0.420 |
Why?
| | Polystyrenes | 1 | 2013 | 36 | 0.420 |
Why?
| | Cobalt | 1 | 2013 | 52 | 0.410 |
Why?
| | Carbon Dioxide | 2 | 2012 | 267 | 0.410 |
Why?
| | Biofuels | 1 | 2012 | 17 | 0.400 |
Why?
| | Singlet Oxygen | 1 | 2012 | 18 | 0.400 |
Why?
| | Polymerization | 1 | 2013 | 126 | 0.400 |
Why?
| | Benzyl Alcohol | 1 | 2012 | 12 | 0.380 |
Why?
| | Diphosphonates | 1 | 2012 | 66 | 0.380 |
Why?
| | Carbon Monoxide | 1 | 2012 | 80 | 0.380 |
Why?
| | Hydroxides | 1 | 2011 | 26 | 0.370 |
Why?
| | Cytochromes c1 | 1 | 2011 | 1 | 0.370 |
Why?
| | Cytochrome c Group | 1 | 2011 | 43 | 0.360 |
Why?
| | Papillomaviridae | 2 | 2019 | 126 | 0.350 |
Why?
| | Indium | 1 | 2010 | 9 | 0.340 |
Why?
| | Photolysis | 1 | 2011 | 91 | 0.340 |
Why?
| | Tin | 1 | 2010 | 9 | 0.340 |
Why?
| | Photosystem II Protein Complex | 2 | 2007 | 16 | 0.340 |
Why?
| | Ruthenium Compounds | 1 | 2010 | 1 | 0.340 |
Why?
| | Tryptophan | 1 | 2011 | 183 | 0.330 |
Why?
| | Nitrogen | 2 | 2019 | 170 | 0.330 |
Why?
| | Nanoparticles | 3 | 2013 | 484 | 0.320 |
Why?
| | Models, Molecular | 7 | 2013 | 1586 | 0.300 |
Why?
| | Lung Neoplasms | 6 | 2024 | 2494 | 0.300 |
Why?
| | Recombination, Genetic | 4 | 2016 | 198 | 0.270 |
Why?
| | Signal Transduction | 4 | 2025 | 5096 | 0.260 |
Why?
| | Molecular Conformation | 5 | 2013 | 152 | 0.260 |
Why?
| | Human papillomavirus 16 | 1 | 2025 | 36 | 0.240 |
Why?
| | Myelin Proteins | 2 | 2016 | 45 | 0.240 |
Why?
| | Deoxycytidine | 4 | 2014 | 176 | 0.240 |
Why?
| | Cottontail rabbit papillomavirus | 1 | 2024 | 4 | 0.230 |
Why?
| | ras Proteins | 1 | 2025 | 151 | 0.220 |
Why?
| | Energy Transfer | 3 | 2013 | 46 | 0.220 |
Why?
| | Monocarboxylic Acid Transporters | 1 | 2024 | 22 | 0.220 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 5 | 2014 | 1695 | 0.220 |
Why?
| | Rhadinovirus | 1 | 2024 | 21 | 0.220 |
Why?
| | RNA, Transfer | 1 | 2025 | 135 | 0.220 |
Why?
| | Solvents | 1 | 2004 | 108 | 0.210 |
Why?
| | Herpesvirus 8, Human | 1 | 2024 | 63 | 0.210 |
Why?
| | Gammaherpesvirinae | 1 | 2024 | 47 | 0.210 |
Why?
| | Sarcoma, Kaposi | 1 | 2024 | 78 | 0.200 |
Why?
| | Janus Kinases | 1 | 2023 | 14 | 0.200 |
Why?
| | Neuroprotective Agents | 1 | 2024 | 132 | 0.200 |
Why?
| | Carcinoma, Basal Cell | 1 | 2004 | 75 | 0.200 |
Why?
| | RNA, Long Noncoding | 1 | 2025 | 181 | 0.200 |
Why?
| | Amines | 1 | 2003 | 40 | 0.200 |
Why?
| | Animals | 23 | 2025 | 37011 | 0.200 |
Why?
| | Genome-Wide Association Study | 3 | 2021 | 1436 | 0.200 |
Why?
| | Evolution, Molecular | 6 | 2014 | 488 | 0.200 |
Why?
| | Herpesviridae Infections | 1 | 2024 | 148 | 0.200 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2024 | 99 | 0.190 |
Why?
| | Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2024 | 117 | 0.190 |
Why?
| | Luminescence | 2 | 2012 | 38 | 0.190 |
Why?
| | Uterine Cervical Neoplasms | 1 | 2025 | 255 | 0.190 |
Why?
| | Interferon Type I | 1 | 2023 | 142 | 0.190 |
Why?
| | Melanoma, Experimental | 2 | 2021 | 113 | 0.180 |
Why?
| | Stress, Physiological | 1 | 2025 | 445 | 0.180 |
Why?
| | Protein Biosynthesis | 2 | 2025 | 434 | 0.180 |
Why?
| | Withanolides | 1 | 2021 | 3 | 0.180 |
Why?
| | Spectrophotometry | 2 | 2012 | 61 | 0.180 |
Why?
| | Poly I-C | 1 | 2021 | 63 | 0.180 |
Why?
| | Lasers | 2 | 2012 | 137 | 0.180 |
Why?
| | Mutation | 4 | 2021 | 3964 | 0.180 |
Why?
| | Thermodynamics | 4 | 2007 | 421 | 0.170 |
Why?
| | Cystadenocarcinoma, Serous | 1 | 2021 | 75 | 0.170 |
Why?
| | Organ Transplantation | 1 | 2004 | 248 | 0.170 |
Why?
| | Hydrogen Bonding | 3 | 2016 | 168 | 0.170 |
Why?
| | Quantum Theory | 2 | 2011 | 87 | 0.170 |
Why?
| | DNA Transposable Elements | 2 | 2014 | 122 | 0.170 |
Why?
| | Edetic Acid | 1 | 2020 | 50 | 0.170 |
Why?
| | Biomimetics | 1 | 2020 | 44 | 0.170 |
Why?
| | Sodium Nitrite | 1 | 2020 | 39 | 0.160 |
Why?
| | Skin Neoplasms | 2 | 2024 | 853 | 0.160 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 2 | 2011 | 1079 | 0.160 |
Why?
| | Circular Dichroism | 2 | 2013 | 151 | 0.160 |
Why?
| | Mitochondria, Heart | 1 | 2019 | 100 | 0.160 |
Why?
| | HMGN1 Protein | 1 | 2018 | 1 | 0.160 |
Why?
| | Immunotherapy | 2 | 2021 | 647 | 0.150 |
Why?
| | alpha-Synuclein | 1 | 2019 | 35 | 0.150 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2024 | 806 | 0.150 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2004 | 683 | 0.150 |
Why?
| | Transcription Factors | 3 | 2022 | 1717 | 0.150 |
Why?
| | Blood | 1 | 2019 | 106 | 0.150 |
Why?
| | Molecular Sequence Data | 6 | 2014 | 2901 | 0.150 |
Why?
| | Adaptor Proteins, Signal Transducing | 2 | 2014 | 429 | 0.140 |
Why?
| | Humans | 36 | 2025 | 137514 | 0.140 |
Why?
| | Genetic Variation | 3 | 2014 | 986 | 0.140 |
Why?
| | Biological Products | 1 | 2021 | 219 | 0.140 |
Why?
| | Imidazoles | 1 | 2018 | 244 | 0.140 |
Why?
| | Buffers | 1 | 2017 | 56 | 0.140 |
Why?
| | Cytoskeletal Proteins | 2 | 2016 | 156 | 0.140 |
Why?
| | Crystallography, X-Ray | 2 | 2013 | 474 | 0.140 |
Why?
| | Cell Cycle Proteins | 1 | 2021 | 614 | 0.130 |
Why?
| | Pseudomonas stutzeri | 1 | 2016 | 2 | 0.130 |
Why?
| | Rhodobacter sphaeroides | 1 | 2016 | 7 | 0.130 |
Why?
| | Cholesterol | 2 | 2021 | 413 | 0.130 |
Why?
| | Vibrio cholerae | 1 | 2016 | 13 | 0.130 |
Why?
| | Munc18 Proteins | 1 | 2016 | 24 | 0.130 |
Why?
| | Proteins | 2 | 2016 | 1012 | 0.130 |
Why?
| | Electric Power Supplies | 2 | 2013 | 52 | 0.130 |
Why?
| | Genome, Human | 3 | 2025 | 424 | 0.130 |
Why?
| | Neurons | 2 | 2022 | 1613 | 0.120 |
Why?
| | Phenothiazines | 2 | 2006 | 8 | 0.120 |
Why?
| | Ovarian Neoplasms | 1 | 2021 | 563 | 0.120 |
Why?
| | Silver Compounds | 1 | 2015 | 5 | 0.120 |
Why?
| | Dendritic Cells | 1 | 2018 | 488 | 0.120 |
Why?
| | Cerium | 1 | 2015 | 14 | 0.120 |
Why?
| | Potentiometry | 2 | 2016 | 4 | 0.120 |
Why?
| | Chemical Precipitation | 1 | 2015 | 38 | 0.120 |
Why?
| | Carbonates | 1 | 2015 | 10 | 0.120 |
Why?
| | HeLa Cells | 1 | 2016 | 640 | 0.110 |
Why?
| | Karyotype | 1 | 2014 | 18 | 0.110 |
Why?
| | Mice | 10 | 2025 | 17843 | 0.110 |
Why?
| | Chemoradiotherapy, Adjuvant | 1 | 2014 | 43 | 0.110 |
Why?
| | Time Factors | 4 | 2013 | 6817 | 0.110 |
Why?
| | Solutions | 1 | 2015 | 170 | 0.110 |
Why?
| | Pan troglodytes | 3 | 2008 | 61 | 0.110 |
Why?
| | Macaca mulatta | 2 | 2022 | 170 | 0.110 |
Why?
| | Fluorouracil | 3 | 2010 | 213 | 0.100 |
Why?
| | Epigenesis, Genetic | 1 | 2018 | 660 | 0.100 |
Why?
| | Survival Analysis | 5 | 2014 | 1320 | 0.100 |
Why?
| | Ions | 1 | 2013 | 72 | 0.100 |
Why?
| | Bacteria | 1 | 2020 | 858 | 0.100 |
Why?
| | Enzyme Activation | 1 | 2015 | 816 | 0.100 |
Why?
| | Particle Size | 2 | 2011 | 394 | 0.100 |
Why?
| | Strepsirhini | 1 | 2012 | 2 | 0.100 |
Why?
| | Lipid Bilayers | 1 | 2013 | 101 | 0.100 |
Why?
| | Phosphoric Acids | 1 | 2012 | 17 | 0.100 |
Why?
| | Tantalum | 1 | 2012 | 3 | 0.100 |
Why?
| | Brain | 2 | 2022 | 2831 | 0.100 |
Why?
| | Pancreatic Neoplasms | 2 | 2014 | 943 | 0.100 |
Why?
| | Anthracenes | 1 | 2012 | 31 | 0.100 |
Why?
| | Asia, Southeastern | 1 | 2012 | 13 | 0.100 |
Why?
| | Acrylates | 1 | 2012 | 47 | 0.100 |
Why?
| | Mutagenesis, Insertional | 1 | 2012 | 65 | 0.100 |
Why?
| | Luminescent Agents | 1 | 2012 | 7 | 0.100 |
Why?
| | Spectrometry, Mass, Electrospray Ionization | 1 | 2012 | 180 | 0.090 |
Why?
| | Pancreatectomy | 1 | 2014 | 252 | 0.090 |
Why?
| | Quartz Crystal Microbalance Techniques | 1 | 2011 | 4 | 0.090 |
Why?
| | Iridium | 1 | 2011 | 7 | 0.090 |
Why?
| | Geography | 1 | 2012 | 197 | 0.090 |
Why?
| | Semiconductors | 1 | 2011 | 40 | 0.090 |
Why?
| | Zinc | 1 | 2015 | 298 | 0.090 |
Why?
| | Molecular Dynamics Simulation | 1 | 2013 | 238 | 0.090 |
Why?
| | Selenium Compounds | 1 | 2011 | 21 | 0.090 |
Why?
| | Biology | 1 | 2012 | 87 | 0.090 |
Why?
| | Data Mining | 1 | 2012 | 116 | 0.090 |
Why?
| | Cadmium Compounds | 1 | 2011 | 32 | 0.090 |
Why?
| | Prevalence | 4 | 2022 | 2719 | 0.090 |
Why?
| | Glutamates | 1 | 2011 | 59 | 0.090 |
Why?
| | Ligands | 3 | 2016 | 665 | 0.090 |
Why?
| | Guanine | 1 | 2011 | 79 | 0.090 |
Why?
| | Genetic Loci | 1 | 2012 | 288 | 0.090 |
Why?
| | Female | 18 | 2025 | 73162 | 0.090 |
Why?
| | Carboplatin | 1 | 2011 | 144 | 0.090 |
Why?
| | Rabbits | 2 | 2024 | 792 | 0.090 |
Why?
| | Cytokines | 1 | 2018 | 2095 | 0.090 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2014 | 1060 | 0.090 |
Why?
| | Mice, Nude | 3 | 2021 | 696 | 0.080 |
Why?
| | Bacterial Proteins | 1 | 2016 | 889 | 0.080 |
Why?
| | Organoplatinum Compounds | 1 | 2010 | 46 | 0.080 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2012 | 619 | 0.080 |
Why?
| | Leucovorin | 1 | 2010 | 83 | 0.080 |
Why?
| | Dimerization | 1 | 2010 | 198 | 0.080 |
Why?
| | Computational Biology | 2 | 2012 | 645 | 0.080 |
Why?
| | Aged | 11 | 2024 | 23798 | 0.080 |
Why?
| | Phosphorylation | 3 | 2025 | 1762 | 0.080 |
Why?
| | DNA, Viral | 2 | 2019 | 362 | 0.080 |
Why?
| | Anti-Bacterial Agents | 1 | 2020 | 1800 | 0.080 |
Why?
| | Interspersed Repetitive Sequences | 1 | 2008 | 5 | 0.080 |
Why?
| | Polymerase Chain Reaction | 1 | 2012 | 1061 | 0.080 |
Why?
| | Chromosome Inversion | 1 | 2008 | 17 | 0.080 |
Why?
| | Metals | 1 | 2010 | 136 | 0.080 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2014 | 807 | 0.070 |
Why?
| | Cell Line, Tumor | 3 | 2025 | 3420 | 0.070 |
Why?
| | Chromosomes | 1 | 2008 | 108 | 0.070 |
Why?
| | Models, Statistical | 1 | 2012 | 667 | 0.070 |
Why?
| | Stereoisomerism | 2 | 2011 | 102 | 0.070 |
Why?
| | Middle Aged | 11 | 2024 | 33355 | 0.070 |
Why?
| | Radiotherapy, Conformal | 2 | 2006 | 70 | 0.070 |
Why?
| | Membranes | 1 | 2007 | 20 | 0.070 |
Why?
| | Hydrogen | 1 | 2008 | 72 | 0.070 |
Why?
| | Male | 15 | 2024 | 67718 | 0.070 |
Why?
| | Genetic Predisposition to Disease | 1 | 2016 | 2420 | 0.070 |
Why?
| | Cercopithecidae | 1 | 2007 | 9 | 0.070 |
Why?
| | Pyrazoles | 1 | 2011 | 427 | 0.070 |
Why?
| | Enzymes | 1 | 2007 | 67 | 0.070 |
Why?
| | Mice, Inbred C57BL | 4 | 2024 | 5792 | 0.070 |
Why?
| | Polyethylene Glycols | 1 | 2012 | 640 | 0.070 |
Why?
| | Antibodies, Monoclonal | 1 | 2014 | 1428 | 0.070 |
Why?
| | Temperature | 1 | 2010 | 680 | 0.070 |
Why?
| | Down-Regulation | 2 | 2020 | 658 | 0.070 |
Why?
| | Barotrauma | 1 | 2006 | 2 | 0.070 |
Why?
| | Bronchogenic Cyst | 1 | 2006 | 7 | 0.070 |
Why?
| | Explosions | 1 | 2006 | 9 | 0.070 |
Why?
| | Aircraft | 1 | 2006 | 23 | 0.060 |
Why?
| | Luminescent Measurements | 2 | 2003 | 76 | 0.060 |
Why?
| | Embolism, Air | 1 | 2006 | 14 | 0.060 |
Why?
| | Intracranial Embolism | 1 | 2006 | 31 | 0.060 |
Why?
| | Database Management Systems | 1 | 2006 | 51 | 0.060 |
Why?
| | Tetrazoles | 1 | 2006 | 40 | 0.060 |
Why?
| | Models, Theoretical | 1 | 2010 | 576 | 0.060 |
Why?
| | Heart Failure | 1 | 2019 | 2222 | 0.060 |
Why?
| | Antineoplastic Agents | 2 | 2010 | 2145 | 0.060 |
Why?
| | Tyrosine | 1 | 2006 | 224 | 0.060 |
Why?
| | Drug Administration Schedule | 2 | 2010 | 784 | 0.060 |
Why?
| | Treatment Outcome | 5 | 2024 | 10821 | 0.060 |
Why?
| | Spectrophotometry, Ultraviolet | 2 | 2016 | 86 | 0.060 |
Why?
| | Databases, Genetic | 1 | 2006 | 237 | 0.060 |
Why?
| | Acetyltransferases | 1 | 2025 | 22 | 0.060 |
Why?
| | Gene Knockout Techniques | 1 | 2025 | 116 | 0.060 |
Why?
| | Tumor Suppressor Proteins | 1 | 2007 | 328 | 0.060 |
Why?
| | Bile Ducts, Extrahepatic | 1 | 2004 | 22 | 0.060 |
Why?
| | Gene Library | 1 | 2025 | 117 | 0.060 |
Why?
| | Disease Models, Animal | 3 | 2020 | 4295 | 0.060 |
Why?
| | Isotopes | 1 | 2004 | 33 | 0.060 |
Why?
| | Hydroxylamines | 1 | 2024 | 4 | 0.060 |
Why?
| | Anthraquinones | 1 | 2004 | 11 | 0.060 |
Why?
| | Oxadiazoles | 1 | 2024 | 35 | 0.060 |
Why?
| | Acetylation | 1 | 2025 | 254 | 0.060 |
Why?
| | Spectroscopy, Fourier Transform Infrared | 2 | 2016 | 86 | 0.050 |
Why?
| | Mitochondrial Membrane Transport Proteins | 1 | 2024 | 43 | 0.050 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 1 | 2004 | 108 | 0.050 |
Why?
| | Clustered Regularly Interspaced Short Palindromic Repeats | 1 | 2024 | 32 | 0.050 |
Why?
| | Iron | 1 | 2006 | 313 | 0.050 |
Why?
| | Structure-Activity Relationship | 2 | 2016 | 586 | 0.050 |
Why?
| | Indicators and Reagents | 1 | 2003 | 109 | 0.050 |
Why?
| | Phthalazines | 1 | 2024 | 45 | 0.050 |
Why?
| | Genome, Viral | 1 | 2024 | 144 | 0.050 |
Why?
| | Ribosomes | 1 | 2025 | 174 | 0.050 |
Why?
| | Liver Neoplasms | 1 | 2010 | 786 | 0.050 |
Why?
| | Nerve Tissue Proteins | 1 | 2007 | 599 | 0.050 |
Why?
| | Feasibility Studies | 2 | 2022 | 950 | 0.050 |
Why?
| | Haplotypes | 1 | 2025 | 491 | 0.050 |
Why?
| | Bile Duct Neoplasms | 1 | 2004 | 123 | 0.050 |
Why?
| | Virus Latency | 1 | 2024 | 85 | 0.050 |
Why?
| | Purines | 1 | 2004 | 176 | 0.050 |
Why?
| | Topotecan | 1 | 2003 | 13 | 0.050 |
Why?
| | Phenazines | 1 | 2002 | 11 | 0.050 |
Why?
| | STAT Transcription Factors | 1 | 2023 | 16 | 0.050 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2014 | 2066 | 0.050 |
Why?
| | Protein Structure, Secondary | 1 | 2004 | 373 | 0.050 |
Why?
| | Nitrogen Isotopes | 1 | 2003 | 72 | 0.050 |
Why?
| | DNA-Binding Proteins | 2 | 2022 | 1507 | 0.050 |
Why?
| | Receptor, Interferon alpha-beta | 1 | 2023 | 34 | 0.050 |
Why?
| | Herpesvirus 4, Human | 1 | 2024 | 167 | 0.050 |
Why?
| | Electron Spin Resonance Spectroscopy | 1 | 2003 | 94 | 0.050 |
Why?
| | Biodiversity | 1 | 2006 | 405 | 0.050 |
Why?
| | CRISPR-Cas Systems | 1 | 2024 | 123 | 0.050 |
Why?
| | Conscious Sedation | 1 | 2003 | 93 | 0.050 |
Why?
| | Angiogenesis Inhibitors | 1 | 2004 | 226 | 0.050 |
Why?
| | Carcinoma, Pancreatic Ductal | 1 | 2006 | 291 | 0.050 |
Why?
| | Maximum Tolerated Dose | 1 | 2003 | 199 | 0.050 |
Why?
| | Disease Progression | 3 | 2021 | 2755 | 0.050 |
Why?
| | Colorectal Neoplasms | 1 | 2010 | 799 | 0.050 |
Why?
| | Mice, Inbred BALB C | 2 | 2021 | 1271 | 0.050 |
Why?
| | STAT3 Transcription Factor | 1 | 2024 | 208 | 0.050 |
Why?
| | Xenograft Model Antitumor Assays | 2 | 2021 | 868 | 0.050 |
Why?
| | Chromosomal Instability | 1 | 2021 | 19 | 0.050 |
Why?
| | Receptor, ErbB-2 | 1 | 2004 | 342 | 0.050 |
Why?
| | Infusions, Intravenous | 1 | 2003 | 411 | 0.050 |
Why?
| | Mendelian Randomization Analysis | 1 | 2021 | 50 | 0.050 |
Why?
| | Nucleic Acid Conformation | 1 | 2025 | 720 | 0.050 |
Why?
| | Interferon-alpha | 1 | 2023 | 198 | 0.050 |
Why?
| | Fallopian Tubes | 1 | 2021 | 31 | 0.050 |
Why?
| | Endosomes | 1 | 2023 | 136 | 0.050 |
Why?
| | Adult | 7 | 2024 | 37821 | 0.050 |
Why?
| | Mice, Knockout | 2 | 2025 | 3020 | 0.050 |
Why?
| | Piperazines | 1 | 2024 | 351 | 0.050 |
Why?
| | Interferon Inducers | 1 | 2021 | 8 | 0.050 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2025 | 538 | 0.050 |
Why?
| | Gene Transfer, Horizontal | 2 | 2014 | 34 | 0.050 |
Why?
| | Glutamine | 1 | 2021 | 104 | 0.040 |
Why?
| | Apoptosis | 2 | 2021 | 2557 | 0.040 |
Why?
| | Microsatellite Repeats | 1 | 2021 | 168 | 0.040 |
Why?
| | Europe | 1 | 2022 | 414 | 0.040 |
Why?
| | ErbB Receptors | 1 | 2004 | 616 | 0.040 |
Why?
| | RNA, Viral | 1 | 2024 | 653 | 0.040 |
Why?
| | Aged, 80 and over | 4 | 2011 | 7593 | 0.040 |
Why?
| | Stents | 1 | 2004 | 528 | 0.040 |
Why?
| | Germany | 2 | 2014 | 121 | 0.040 |
Why?
| | Combined Modality Therapy | 3 | 2011 | 1241 | 0.040 |
Why?
| | Apelin | 1 | 2019 | 10 | 0.040 |
Why?
| | Carcinoma, Lewis Lung | 1 | 2019 | 15 | 0.040 |
Why?
| | Nitrites | 1 | 2020 | 84 | 0.040 |
Why?
| | Promoter Regions, Genetic | 1 | 2024 | 1255 | 0.040 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2021 | 190 | 0.040 |
Why?
| | Heart Function Tests | 1 | 2019 | 61 | 0.040 |
Why?
| | Neoadjuvant Therapy | 2 | 2014 | 405 | 0.040 |
Why?
| | Neurodegenerative Diseases | 1 | 2021 | 137 | 0.040 |
Why?
| | Quantitative Trait Loci | 1 | 2021 | 381 | 0.040 |
Why?
| | Double-Blind Method | 1 | 2024 | 1987 | 0.040 |
Why?
| | Gene Expression Regulation | 2 | 2019 | 2615 | 0.040 |
Why?
| | Tumor Cells, Cultured | 1 | 2021 | 957 | 0.040 |
Why?
| | Sleep Apnea, Obstructive | 1 | 2003 | 291 | 0.040 |
Why?
| | Nuclear Localization Signals | 1 | 2019 | 18 | 0.040 |
Why?
| | Metabolic Networks and Pathways | 1 | 2020 | 182 | 0.040 |
Why?
| | Drug Resistance, Bacterial | 1 | 2020 | 183 | 0.040 |
Why?
| | Synteny | 1 | 2018 | 15 | 0.040 |
Why?
| | Carcinoma, Renal Cell | 1 | 2021 | 214 | 0.040 |
Why?
| | Radiotherapy Dosage | 2 | 2011 | 267 | 0.040 |
Why?
| | Primary Cell Culture | 1 | 2019 | 172 | 0.040 |
Why?
| | Genomics | 2 | 2018 | 793 | 0.040 |
Why?
| | Th1 Cells | 1 | 2018 | 143 | 0.040 |
Why?
| | Transcription, Genetic | 1 | 2024 | 1458 | 0.040 |
Why?
| | Drug Therapy, Combination | 1 | 2021 | 1060 | 0.040 |
Why?
| | CpG Islands | 1 | 2018 | 160 | 0.040 |
Why?
| | Drug Synergism | 1 | 2018 | 379 | 0.040 |
Why?
| | Epigenomics | 1 | 2018 | 115 | 0.030 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2021 | 531 | 0.030 |
Why?
| | Mitochondria | 1 | 2024 | 947 | 0.030 |
Why?
| | Pseudomonas aeruginosa | 1 | 2020 | 353 | 0.030 |
Why?
| | Biofilms | 1 | 2020 | 262 | 0.030 |
Why?
| | Cytochrome-c Peroxidase | 1 | 2016 | 1 | 0.030 |
Why?
| | Risk Factors | 3 | 2021 | 10356 | 0.030 |
Why?
| | Oxygen Consumption | 1 | 2019 | 684 | 0.030 |
Why?
| | Netherlands | 1 | 2016 | 88 | 0.030 |
Why?
| | Echocardiography | 1 | 2019 | 659 | 0.030 |
Why?
| | Gene Deletion | 2 | 2008 | 393 | 0.030 |
Why?
| | Kidney Neoplasms | 1 | 2021 | 400 | 0.030 |
Why?
| | Databases, Factual | 1 | 2022 | 1351 | 0.030 |
Why?
| | Oxidoreductases | 1 | 2016 | 93 | 0.030 |
Why?
| | Heme | 1 | 2016 | 79 | 0.030 |
Why?
| | Monocytes | 1 | 2018 | 568 | 0.030 |
Why?
| | Membrane Potentials | 1 | 2016 | 294 | 0.030 |
Why?
| | Survival Rate | 2 | 2014 | 1980 | 0.030 |
Why?
| | Polymorphism, Genetic | 2 | 2008 | 658 | 0.030 |
Why?
| | Cell Nucleus | 1 | 2019 | 615 | 0.030 |
Why?
| | Recombinant Proteins | 1 | 2018 | 1357 | 0.030 |
Why?
| | Myocytes, Cardiac | 1 | 2019 | 528 | 0.030 |
Why?
| | Epithelial Cells | 1 | 2021 | 1099 | 0.030 |
Why?
| | Switzerland | 1 | 2014 | 38 | 0.030 |
Why?
| | Cohort Studies | 2 | 2016 | 5730 | 0.030 |
Why?
| | Solid-Phase Synthesis Techniques | 1 | 2014 | 15 | 0.030 |
Why?
| | Nogo Proteins | 1 | 2014 | 10 | 0.030 |
Why?
| | Sex Characteristics | 1 | 2019 | 766 | 0.030 |
Why?
| | Transcription Termination, Genetic | 1 | 2014 | 19 | 0.030 |
Why?
| | Base Sequence | 2 | 2008 | 2180 | 0.030 |
Why?
| | Chromatin | 1 | 2018 | 524 | 0.030 |
Why?
| | 1,2-Dipalmitoylphosphatidylcholine | 1 | 2013 | 10 | 0.030 |
Why?
| | Hominidae | 1 | 2014 | 85 | 0.030 |
Why?
| | Age Distribution | 1 | 2014 | 391 | 0.030 |
Why?
| | Gene Expression | 1 | 2019 | 1505 | 0.030 |
Why?
| | Administration, Intravenous | 1 | 2014 | 154 | 0.030 |
Why?
| | Sex Distribution | 1 | 2014 | 378 | 0.030 |
Why?
| | Transcriptome | 1 | 2019 | 974 | 0.030 |
Why?
| | Protein Conformation | 1 | 2016 | 930 | 0.030 |
Why?
| | Cell Proliferation | 1 | 2021 | 2482 | 0.030 |
Why?
| | Lung Diseases | 1 | 2020 | 768 | 0.030 |
Why?
| | Cell Line | 1 | 2019 | 2852 | 0.030 |
Why?
| | Parkinson Disease | 1 | 2019 | 495 | 0.030 |
Why?
| | Colloids | 1 | 2013 | 60 | 0.030 |
Why?
| | Dielectric Spectroscopy | 1 | 2012 | 2 | 0.030 |
Why?
| | Phosphatidylcholines | 1 | 2013 | 148 | 0.020 |
Why?
| | Madagascar | 1 | 2012 | 47 | 0.020 |
Why?
| | Click Chemistry | 1 | 2013 | 49 | 0.020 |
Why?
| | Cisplatin | 1 | 2014 | 318 | 0.020 |
Why?
| | Selection, Genetic | 1 | 2014 | 262 | 0.020 |
Why?
| | Bayes Theorem | 1 | 2014 | 407 | 0.020 |
Why?
| | Prospective Studies | 3 | 2014 | 7598 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2019 | 4206 | 0.020 |
Why?
| | RNA, Messenger | 1 | 2019 | 2838 | 0.020 |
Why?
| | Coumarins | 1 | 2011 | 20 | 0.020 |
Why?
| | Nuclear Magnetic Resonance, Biomolecular | 1 | 2013 | 340 | 0.020 |
Why?
| | Nitrophenols | 1 | 2011 | 34 | 0.020 |
Why?
| | Pemetrexed | 1 | 2011 | 33 | 0.020 |
Why?
| | Cell Differentiation | 1 | 2018 | 1979 | 0.020 |
Why?
| | Spectrum Analysis | 1 | 2011 | 91 | 0.020 |
Why?
| | Biphenyl Compounds | 1 | 2011 | 63 | 0.020 |
Why?
| | Protein Binding | 1 | 2016 | 2229 | 0.020 |
Why?
| | Infusion Pumps, Implantable | 1 | 2010 | 25 | 0.020 |
Why?
| | Cell Membrane | 1 | 2013 | 751 | 0.020 |
Why?
| | Rats | 1 | 2019 | 5676 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2014 | 1740 | 0.020 |
Why?
| | 3' Flanking Region | 1 | 2008 | 7 | 0.020 |
Why?
| | Sequence Homology, Nucleic Acid | 1 | 2008 | 155 | 0.020 |
Why?
| | Genotype | 1 | 2014 | 1920 | 0.020 |
Why?
| | Adenocarcinoma | 2 | 2007 | 937 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2016 | 3546 | 0.020 |
Why?
| | Liver Neoplasms, Experimental | 1 | 2007 | 31 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2010 | 892 | 0.020 |
Why?
| | Species Specificity | 1 | 2008 | 593 | 0.020 |
Why?
| | Repetitive Sequences, Nucleic Acid | 1 | 2007 | 113 | 0.020 |
Why?
| | Software Design | 1 | 2006 | 24 | 0.020 |
Why?
| | Endogenous Retroviruses | 1 | 2007 | 36 | 0.020 |
Why?
| | Quaternary Ammonium Compounds | 1 | 2006 | 53 | 0.020 |
Why?
| | Exons | 1 | 2007 | 349 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2014 | 2193 | 0.020 |
Why?
| | Cations | 1 | 2006 | 85 | 0.020 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2006 | 105 | 0.020 |
Why?
| | Precancerous Conditions | 1 | 2007 | 170 | 0.020 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2006 | 94 | 0.020 |
Why?
| | Alleles | 1 | 2008 | 891 | 0.020 |
Why?
| | Patient Compliance | 1 | 2010 | 586 | 0.020 |
Why?
| | Cell Lineage | 1 | 2007 | 346 | 0.020 |
Why?
| | Fatal Outcome | 1 | 2006 | 305 | 0.020 |
Why?
| | Colonic Neoplasms | 1 | 2007 | 258 | 0.010 |
Why?
| | BALB 3T3 Cells | 1 | 2004 | 1 | 0.010 |
Why?
| | Biological Evolution | 1 | 2008 | 466 | 0.010 |
Why?
| | Data Interpretation, Statistical | 1 | 2006 | 352 | 0.010 |
Why?
| | Neoplasms | 1 | 2018 | 2666 | 0.010 |
Why?
| | Sequence Analysis, DNA | 1 | 2006 | 812 | 0.010 |
Why?
| | DNA Probes | 1 | 2002 | 60 | 0.010 |
Why?
| | Biomarkers | 1 | 2014 | 4172 | 0.010 |
Why?
| | Cell Division | 1 | 2004 | 795 | 0.010 |
Why?
| | Software | 1 | 2007 | 670 | 0.010 |
Why?
| | Mice, Transgenic | 1 | 2007 | 2182 | 0.010 |
Why?
| | Diagnosis, Differential | 1 | 2006 | 1486 | 0.010 |
Why?
| | Internet | 1 | 2006 | 656 | 0.010 |
Why?
| | Child | 1 | 2022 | 22037 | 0.010 |
Why?
| | Enzyme Inhibitors | 1 | 2004 | 845 | 0.010 |
Why?
| | Models, Biological | 1 | 2007 | 1775 | 0.010 |
Why?
| | Age Factors | 1 | 2007 | 3301 | 0.010 |
Why?
| | Algorithms | 1 | 2006 | 1702 | 0.010 |
Why?
| | Palliative Care | 1 | 2004 | 738 | 0.010 |
Why?
| | Retrospective Studies | 2 | 2006 | 15628 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 1 | 2006 | 2681 | 0.010 |
Why?
| | Prognosis | 1 | 2004 | 4031 | 0.010 |
Why?
| | Risk Assessment | 1 | 2004 | 3439 | 0.010 |
Why?
|
|
Meyer's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|